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ABSTRACT
Diabetes currently affects 9.3% of the U.S. population totaling
$245 billion annually in U.S. direct and indirect healthcare
costs. Current therapies for diabetes are limited in their ability to
control blood glucose and/or enhance insulin sensitivity. Therefore,
innovative and efficacious therapies for diabetes are urgently
needed. Herein we describe a fluorescent insulin reporter system
(preproinsulin-mCherry, PPI-mCherry) that tracks live-cell insulin
dynamics and secretion in pancreatic b-cells with utility for high-
content assessment of real-time insulin dynamics. Additionally,
we report a new modality for sensing insulin granule packaging in
conventional high-throughput screening (HTS), using a hybrid cell-
based fluorescence polarization (FP)/internal FRET biosensor using
the PPI-mCherry reporter system. We observed that bafilomycin, a
vacuolar H+ ATPase inhibitor and inhibitor of insulin granule
formation, significantly increased mCherry FP in INS-1 cells with
PPI-mCherry. Partial least squares regression analysis demon-
strated that an increase of FP by bafilomycin is significantly
correlated with a decrease in granularity of PPI-mCherry signal in
the cells. The increased FP by bafilomycin is due to inhibition of
self-Förster resonant energy transfer (homo-FRET) caused by the
increased mCherry intermolecular distance. FP substantially de-
creases when insulin is tightly packaged in the granules, and the
homo-FRET decreases when insulin granule packaging is inhibited,
resulting in increased FP. We performed pilot HTS of 1782 FDA-
approved small molecules and natural products from Prestwick
and Enzo chemical libraries resulting in an overall Z 0-factor of
0.52 – 0.03, indicating the suitability of this biosensor for HTS. This
novel biosensor enables live-cell assessment of protein–protein
interaction/protein aggregation in live cells and is compatible with
conventional FP plate readers.
INTRODUCTION
R
educed insulin secretion or increased insulin resis-
tance leads to serious metabolic disturbances that
characterize diabetes mellitus.1 Diabetes affects *10%
of the U.S. population totaling $245 billion annually in
total medical costs.2 Injectable insulin is a well-known therapy
for type-1 (insulin-dependent) diabetes. However, most diabetes
is type-2 diabetes (T2D) associated with obesity, Western diet,
and sedentary lifestyle. In fact T2D represents greater than 90%
of all diabetes cases in the United States.3 In addition, T2D dia-
betes incidence also increases with age—23% of individuals over
age 60 have diabetes4—and aging populations will create in-
creased diabetes costs in the future. Clearly, given the escalating
magnitude of T2D costs and complications, therapeutic innova-
tion for T2D treatment remain of high interest and importance.
Need for New Antidiabetics
Measurement of glycated hemoglobin (HbA1c [or A1c]) is
used as a surrogate index of past blood glucose levels to di-
agnose and subsequently monitor/treat diabetes. Currently
the diagnosis of diabetes is confirmed when HbA1c rises
above 6.5%.5 The large market size for T2D drugs and need for
better glycemic (A1c) control or better tolerated drugs create
a constant search for new treatments.
The main pharmacological approaches for treating early
stage (noninsulin-dependent) T2D are by (1) alleviating insulin
resistance in peripheral tissues thereby making endogenous
insulin more effective with insulin sensitizers; (2) stimulating
additional endogenous insulin secretion in the pancreas with
secretagogues; and (3) increasing glucose uptake by peripheral
tissues, including fat. The first-line antidiabetes drug, generic
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metformin, acts primarily by decreasing glucose output from
the liver, but has side effects (gastrointestinal events and lactic
acidosis)6 and does not always maintain sufficient glycemic
control over time.7 First-line treatment typically starts with
diet/exercise modification progressing to oral monotherapy
(typically metformin) to combinationoral therapy to exogenous
insulin.8 Despite numerous classes of T2D drugs, only
*36% of diabetes patients achieve the A1c goal of £7%.9 In
addition, some diabetes drugs (e.g., thiazolidinediones) actually
lead to weight gain, an undesirable side effect and itself a risk
factor for diabetes.
New classes of drugs that normalize blood glucose by
stimulating glucose-dependent insulin secretion (i.e., post-
meal) are the insulin incretins. The incretins act through the
glucagon-like peptide-1 receptor (GLP-1R), which is the re-
ceptor for the gut hormone glucagon-like peptide-1 (GLP-1).
Much of the recent pursuit of antidiabetic drug development
has focused on GLP-1R or the enzyme that degrades it, DPP-4
(dipeptidyl peptidase-4)10; however, to date, there has not
been clinical success in molecularly targeting GLP-1R with
small orally available molecule agonists.
The mechanism of action of GLP-1 is unique in that it in-
duces glucose-dependent stimulation of insulin secretion while
suppressing glucagon production. Compounds that cause
glucose-dependent insulin secretion are highly attractive be-
cause when blood glucose levels are in the normal fasting
range, GLP-1 does not stimulate insulin secretion, rather only
when blood glucose levels rise. These agents generally do not
cause hypoglycemia as do the legacy insulin secretagogues,
including the sulfonylureas (SFUs—glyburide, glipizide, and
glimepiride) and the glinides (repaglinide and nateglinide),
which have substantial side effects, including acute hypogly-
cemia and weight gain. The major downside to current FDA-
approved incretin mimetics includes peptide administration
through subcutaneous injection. Although the GLP-1 receptor
has so far been refractory to small molecule drug development,
other molecules in the pathway or different pathways in the cell
that might elicit similar biological responses may be amenable
to small molecule agonism/antagonism.
Insulin Cell Biology as an Assay Development Target
The ability to secrete physiologically active insulin is reg-
ulated at multiple steps, each providing the opportunity for
pharmacological intervention (Fig. 1). Insulin production
begins with regulated transcription and subsequent transla-
tion of the preproinsulin (PPI) peptide. PPI is sequentially
formed by a signal peptide, the B chain, the C peptide, and the
A chain. Proteolytic cleavage of the signal peptide forms
proinsulin. Subsequent removal of C peptide from proinsulin
produces active mature insulin. Several key cell biological
events must occur for insulin maturation: (1) transcription,
(2) translation and translocation in the endoplasmic reticulum,
(3) folding, oxidation (disulfide bonding between peptide
chains), and signal peptide cleavage, (4) Golgi transport,
vesicle packaging into secretory vesicles, and (5) protease/
carboxypeptidase cleavage to produce mature insulin. Insulin
maturation also requires acidification of secretory vesicles to a
pH typically near 5.0. Once mature insulin is formed, it is
stored inside the cell as dense-core granules in two distinct
populations; (1) the readily releasable pool (RRP) for
Fig. 1. Insulin secretion mechanisms described in pancreatic beta
cells (adapted from Rorsman1). (A) Secretion signaling elements of
the b-cell: SUR-sulfonylurea receptor, ATP-regulated K+ channel,
Ca2+ channel, and mechanistic tool compounds. (B) Biphasic in-
sulin response to glucose, and (C) insulin secretion from readily
releasable pool (RRP) and ATP-dependent replenishment by the
reserve pool (RP).
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immediate response to stimulus, and (2) the reserve pool for
replenishment of the RRP (Fig. 1C).11
The physiological response to glucose is a two-stage (bi-
phasic) release response consisting of a sharp rise, followed by
a gradual second phase release (Fig. 1B). The first phase of
insulin release requires a rapid rise in intracellular Ca2+ and
corresponds to the immediate release of insulin granules from
the RRP. These mature insulin vesicles sit near the membrane
waiting for an appropriate stimulus to trigger membrane fu-
sion and release. A portion of the remaining granules (reserve
pool) are mobilized to replenish the RRP and sustain insulin
secretion.1 Pharmacological agents that directly modulate
insulin secretion target various steps in the insulin synthesis
and secretion pathways. Complex signaling networks from
ion channels (potassium and voltage-dependent Ca2+ chan-
nels) to G protein–coupled receptors regulate insulin secre-
tion. Known tool compounds that alter insulin synthesis/
maturation and secretion are shown in Figure 1A.
Homo-FRET and Fluorescence Polarization in HTS
When fluorescent molecules are excited by plane-polarized
light, the emitted light retains the polarization of the excita-
tion source due to selective absorption of photons by mole-
cules where the absorption dipole moment is aligned with the
polarization of the incident photon. The observed fluores-
cence anisotropy is decreased when molecular rotation hap-
pens in solution during the lifetime of the excited state.
Rotation of the transition dipole along with the molecule will
correspondingly rotate the polarization of the emitted photon.
Additionally, increasing molecular size (hydrodynamic radi-
us) slows the tumbling rate of the fluorophore and slows the
observed depolarization of emission. The fluorescence polar-
ization (FP) phenomenon has been widely used to assay
binding events in biochemical systems because the tumbling
rate of a fluorophore can change dramatically upon binding
events (e.g., small molecule dye binding to a larger protein).
When a single fluorophore is in sufficiently high con-
centration, Förster resonance energy transfer (FRET) can
occur between fluorophores of the same type, called homo-
FRET.12,13 In the homo-FRET interaction, an excited state hops
nonradiatively from one fluorescent molecule to another
through a dipole–dipole interaction. When there is a sub-
stantially high local concentration of a fluorophore or the
intermolecular distance is below 10 nm, homo-FRET can
occur. When excitation occurs with plane-polarized light and
homo-FRET occurs, the energy transfer from one fluorophore
to the next causes a relative decrease in the FP signal due to
randomization of the transition dipole through successive
charge transfer events.14 We reasoned we could exploit the
high-density packaging of insulin granules to utilize homo-
FRET. Homo-FRET can be used to assess protein dynamics in
live cells by monitoring the FP anisotropy using a conven-
tional FP plate reader. In this study, we exploit homo-FRET
through FP (HF-FP) to assess the dynamics of insulin granule
packaging using a genetically encoded mCherry-fusion with
the insulin B and C peptide that colocalizes with endogenous
insulin granules.
HTS and Screening for Insulin-Modulating Compounds
Numerous high-throughput screening (HTS) campaigns
have been performed in the diabetes therapeutic area directed
at both discrete molecular and phenotypic targets thought to
modulate some aspect of insulin production and release. In
recent years, compounds that stimulate the incretin effect—
glucose-dependent insulin secretion—have been of particular
interest to pharmaceutical companies. Insulin granule pack-
aging is a critical upstream step in the insulin release cascade;
however, the factors or compounds that affect insulin granule
packaging have not been widely investigated and insulin
granule packaging remains inaccessible in HTS. Agents that
influence insulin biosynthesis may alter insulin granule
packaging by increasing or decreasing insulin synthesis at the
level of gene transcription, translation, or posttranslational
modification. Also, compounds that affect insulin secretion
may modify insulin granule packaging. Inhibitors of insulin
release, such as mitochondrial toxins, may cause mature in-
sulin granules to be more tightly packaged and factors that
increase insulin secretion may lead to a lesser amount of
packaged insulin. Therefore, a simple plate-reader-based
assay to monitor insulin packaging will provide an invaluable
tool for investigating potential insulin-modulating com-
pounds and also represents a valid phenotypic target for en-
hancing insulin production/processing.
MATERIALS AND METHODS
PPI mCherry Reporter Constructs
Previous studies using a green fluorescent protein (GFP) fu-
sion to the C peptide of mouse PPI II produced localization with
and release of endogenous insulin.15 We have utilized this
approach toward labeling endogenous insulin through fluores-
cently tagged PPI. Additionally, we have replaced the GFP
moiety with the much less pH-sensitive mCherry to prevent loss
of fluorescent signal during vesicle maturation, as insulin vesi-
cles undergo acidification to as low as pH 4.5 during maturation.
We have also included the 30-UTR region of the PPI mRNA as
this has been shown to confer a glucose-induced increase in
mRNA stability.16,17 Our constructs were packaged in a pLenti
delivery system, and the reporter signal was driven by either
YI ET AL.
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cytomegalovirus (CMV) or mouse insulin promoter. All con-
structs were made using pLenti X2 Puro Empty (w609-1; Ad-
dgene). To produce mCherry with an insulin-targeting sequence
at its N-terminus driven by a CMV promoter, we cloned the
portionofmouse insulin II upstreamofGFP from theAdlox-InC-
emGFP construct (a gift from Dr. Peter Drain),15 including the
signal peptide, B chain, and the C peptide up to Pro72, inserting
into the EcoRI and BamHI sites of pmCherry-N1 (Fig. 2A).
Cell Culture, Transfection, and Flow Cytometry
Rat insulinoma (INS-1) cells were cultured in RPMI-1640
medium (Sigma -Aldrich) with 10% fetal bovine serum (FBS),
2 mM glutamine, 1 mM sodium pyruvate, 10 mM HEPES,
0.05 mM 2-mercaptoethanol, and 1% penicillin and strepto-
mycin. The cells were grown at 37C with 5% CO2 in fully
humidified air. For transfection, INS-1 cells were transfected
with our reporter construct driven by CMV promoter using
Lipofectamine 2000 (Invitrogen). Two days following the
transfection, cells were selected with 350 mg/mL of G418
until colonies were visible. After the antibiotic selection, the
transfected INS-1 cells were subjected to FACS sorting to pool
cells according to mCherry fluorescence intensity (low, me-
dium, and high), and the cells that highly expressed mCherry
fluorescence were used for our experiments.
Human Islet Cell Culture, Viral Transduction,
and Flow Cytometry
Human pancreatic islets were obtained from the National
Disease Research Interchange (NDRI) or Prodo lab. Body mass
index of the donors was within the normal range. The purity
and viability of islets ranged from
85% to 95%. Handling of human
islets was carried out according to
legal provisions and rules of the
North Carolina Central University.
However, review of the Institu-
tional Review Board was exempt.
The islets were dispersed into a
single cell suspension by brief di-
gestion with trypsin and allowed
to attach and recover overnight.
The following day, islets were
transduced with lentivirus parti-
cles. The lentivirus particles were
generated in HEK293 cells using
the PPI-mCherry reporter being
expressed under control of mouse
PPI II promotor. Following 3 days
of viral transduction, the maxi-
mum fluorescent signal intensity was observed and flow cy-
tometry was performed to isolate mCherry-positive cells. Sorted,
mCherry-positive cells were stained with Hoechst-33342 and
YoYo-1 iodide and high-content imaging was performed using
a BD pathway 855 microscope (Becton Dickenson) to determine
viability and yield of b-cells.
Immunofluorescence
Cells were grown on poly-d-lysine (50mg/mL)-coated BD
Falcon culture slides and were fixed with 4% paraformaldehyde
(Fisher Scientific) and washed with phosphate-buffered saline
(PBS) three times. Cells were permeabilized for 10 min in PBS
containing 0.2% Triton X-100 in PBS (TPBS) and blocked with
5% bovine serum albumin (BSA) in TPBS buffer for 1 h. Cells
were incubated with primary guinea pig anti-insulin antibody
(1:100; Dako) or mouse anti-glucagon antibody (Abcam)
diluted in TPBS containing 1% BSA overnight at 4C. Cells were
then washed and incubated for 1 h with secondary AlexaFluor
488-conjugated secondary antibody (1:500; Life Technology).
Images were taken using both a Nikon confocal microscope
(Nikon Eclipse-C) and a BD pathway 855 microscope.
Glucose-Stimulated Insulin Secretion
The parental INS-1 cells and the transfected cells were
seeded at a density of 5 · 105 cells/well in six-well plates in
complete growth medium and were grown to 90% confluence.
The cells were washed with PBS and maintained for 2 h in
glucose-free Dulbecco’s modified Eagle’s medium (DMEM).
The cells were then incubated for 1 h at 37C in 2 mL of DMEM
containing low glucose (5.6 mM), high glucose (25 mM) alone,
Fig. 2. Schematic of homo-FRET detection through fluorescence polarization (FP) for the sensitive
monitoring of insulin granule packaging in live cells with insulin shown in yellow and mCherry
shown in red. (A) Free insulin-mCherry with polarized excitation and emission with conserved
polarization. (B) Mixed mCherry-insulin and endogenous insulin within a dense core granule. Plane
polarized excitation of mCherry and subsequent hopping of the excited state, leading to emission
with randomized polarization. MP indicates that relative millipolarization units are high for (A) and
low for (B).
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and high glucose (25 mM) in the presence of 10 nM Exendin-4
(Cat. No. 1933; TOCRIS Bioscience) or 10 mM nifedipine (Cat.
No 151743; MP Biomedicals, LLC). Following incubation,
supernatants were collected to determine secreted insulin
contents.
Quantification of Secreted Insulin
Following glucose-stimulated insulin secretion (GSIS),
800 mL of harvested cultured medium and human insulin
standard were directly deposited onto nitrocellulose mem-
brane using a minifold-1 dot-blot system (Whatman, Inc.),
and the membrane was scanned using the 680 nm channel on
an Odyssey imaging system (Li-Cor Biosciences) to detect
mCherry signal (excitation 560/40 nm and emission 630/
75 nm). In addition, the membranes were blocked for 1 h then
probed with guinea pig anti-insulin (1:5,000; Dako) followed
with secondary antibody (LI-COR IRDye 800 donkey anti-
guinea pig at 1:5,000 dilution). The dot-blot was scanned and
quantified with the Odyssey infrared imaging system.
Tracking of Insulin Transport
in Live Cells (Live Cell Imaging)
Transfected INS-1 cells were seeded onto a 96-well poly-d-
lysine-coated imaging plate (BD Bioscience) and were grown
to 70% confluence. Following 2 h incubation in glucose-free
DMEM, the medium was replaced with DMEM containing
25 mM glucose with 10 nM Exendin-4. Plates were immedi-
ately imaged with a BD pathway 855 microscope, and auto-
mated image analysis was performed using Cell Profiler
software to quantitate mCherry intensity and granularity/
textural features.
Bafilomycin as a Positive Control
for HF-FP Assay Development
Transfected INS-1 cells were plated on a 96-well poly-d-
lysine-coated, NUNC black/clear bottom tissue culture-treated
imaging plates at cell density of 1.0 · 105 cell/well and incu-
bated for 2 days until 95% confluence was reached. To deter-
mine the effective concentration and incubation time of
bafilomycin for HF-FP assay development, cells were incubated
in a medium containing bafilomycin (12.5–200 nM) for 1, 2, 4,
or 6 h. The entire volume of media (200mL) was removed and
150mL of media was added by hand using a multichannel pi-
pette. Immediately after media change, FP was measured using
a PHERAstar microplate reader (BMG LABTECH) with the
FP module (excitation, 590-50nm; emission, 675-50 nm;
focal height, 4.8; Flashes per well, 200/well; cycle time, 300 ms/
well). FP values were expressed in millipolarization (mP)
units and the mP values were calculated using the equation
mP = 1,000 · (Ik - It)/(Ik + It), where Ik is the parallel emission
intensity and It is the perpendicular emission intensity
measurements. Automatic gain adjustment was optimized to
achieve a target mP value of 400 and gain settings were fixed
for the duration of screening.*
High-Content and PLS Regression Analysis
Transfected INS-1 cells were seeded at a density of 5 · 105
on 96-well NCNC plate and cultured for 2 days. Then, cells
were treated with 0.1–200 nM of bafilomycin for 4 h and FP
was measured. Following FP, cells were fixed with 4%
formaldehyde and stained with 10 mg/mL Hoechst-33342.
The cells were then washed once with PBS and imaged on a
BD Pathway 855 BioImager using a 20·/0.75 NA Olympus
UPlanApo objective lens. Images were analyzed using Cell-
Profiler software18 and mCherry features were tabulated from
cells, including granularity, texture, and average mCherry
intensity. Granularity was calculated within CellProfiler
using the MeasureGranularity module. Partial least squares
(PLS) regression was performed using JMP11 software (SAS)
for exploratory data analysis to find linear combinations of
cellular features from high-content analysis that were highly
correlated with the measured FP result to aid in under-
standing insulin granule phenotypes with respect to the
measured FP signal.
Pilot Screening in 384-Well Format
To validate HF-FP for HTS using laboratory automation,
pilot screening was performed in the 384-well format. The
assay protocol is presented in Table 1. Two highly annotated
small-molecule libraries were used, including a 1,280-molecule
FDA-approved drug set (Prestwick Chemical Library) and 502
purified natural products (Enzo Life Sciences). The compound
libraries were plated in Axygen 384-well rigid PCR plates (Cat.
No. 321-67-051) in 100% DMSO at 5 mM for single concen-
tration screening.
Transfected INS-1 cells were plated in 384-well poly-d-
lysine-coated, NUNC black/clear bottom tissue culture-treated
imaging plates (NUNC No. 152029). Twenty-five microliters of
prewarmed growth medium was added to each well using a
Mutidrop-384 (Thermo/Fisher), followed by 25 mL of cell
suspension (80,000 viable cells/well). The cells were cultured
for 48 h at 37C with 5% CO2. Forty microliters of growth
medium was removed and 50 mL of fresh medium was added
with a BioMek NX using 96-well head with AP96 P20 tips. A
Pintool array (V&P Scientific) was used for compound
*mP values are arbitrary and highly dependent on detector gain, however, mP
values for controls were similar day to day.
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addition for an *1,000-fold dilution. Fifty nanoliters of 5 mM
compound in DMSO was added to columns 3–22 of the plate
for single-concentration screening. Fifty nanoliters of DMSO
and 100 mM of bafilomycin were added to negative control
wells in columns 1 and 2 and positive control wells in column
23 and 24, respectively. Following 4 h of incubation with
compounds, media were changed by Biomek NX workstation,
and then FP was measured using a PHERAstar microplate
reader (excitation, 590-50 nm; emission, 675-50 nm; focal
height, 7.2; Flashes per well, 200/well; cycle time, 300 ms/
well). Compounds were identified as hits if the mP values were
above or below the 95% CL (approximately m – 3s) for the
samples in the plate. Instant JChem was used for structure
database management, search and prediction (Instant JChem
15.1.12, 2015; ChemAxon [http://www.chemaxon.com]).
EC50 dose–response determination was performed in trip-
licates in a 384-well plate. Compounds selected from the pilot
screen were diluted in a 10-point twofold format using an HP
D300 digital dispenser (HP) that directly dispenses compounds
to each well of the cell plate, thereby avoiding a serial dilu-
tion step. Two microliters of selected hits and bafilomycin
(100 mM) were added to each reservoir. The controls were
applied to column 1–2 (DMSO—minimum signal control) and
23–24 (83 nM of bafilomycin—maximum signal control), and
different concentrations of the test compounds were applied
to column 3–22 of the cell plate. The concentrations ranged
from 16.67 to 0.03 mM for Prestwick compounds, and 8.33 to
0.02 mM for the Natural product compounds. The final DMSO
concentration was normalized to 0.2% by the HP D300.
RESULTS
We have developed a genetically encoded insulin reporter
system based on a PPI peptide-mCherry fluorescent protein
fusion to enable tracking of insulin dynamics in live cells using
both high-throughput and high-content screening, sorting of
b-cells, and for rapid determination of GSIS by detecting se-
creted mCherry fluorescence. Initial studies have focused on
utilization and validation of the insulin reporter system for HTS
to detect compounds that significantly alter insulin granule
packaging. To achieve this goal, we have developed a unique
modality for HTS using FP anisotropy to detect changes in the
packaging of mCherry in living cells through homo-FRET.
Figure 2A shows a schematic of normal fluorescence an-
isotropy for the PPI-mCherry protein. Upon excitation with
plane-polarized light, the fluorescence emission exhibits high
polarization anisotropy. Figure 2B shows a schematic of
homo-FRET between mCherry molecules inside a dense-core
insulin granule. The plane-polarized excitation is absorbed
and the excited state hops from molecule to molecule by FRET,
thereby reducing the polarization anisotropy.
Validation and Utility of the PPI-mCherry Biosensor
We established a reporter construct consisting of mCherry
fused with PPI under CMV promoter control (Fig. 3A) that
fluorescently labels endogenous insulin granules. Figure 3B
shows transfected INS-1 cells with PPI-mCherry reporter and
Figure 3C demonstrates excellent colocalization between im-
munostained endogenous insulin and PPI-mCherry in trans-
fected INS-1 cells. To establish the utility in primary human
cells, human pancreatic islets were virally transduced with the
PPI-mCherry reporter construct (driven by the mouse insulin
Table 1. Protocol for HF-FP High-Content Assay
Step Parameter Value Description
1 Plate cells 25 + 25 mL 80,000 PPI-mCherry INS-1
cells/well
2 Cell attachment 48 h 37C, 5% CO2
3 Media change Removed 40 mL and added
50 mL of media
4 Add vehicle 50 nL DMSO control added to
columns 1 and 2
5 Add bafilomycin 50 nL Bafilomycin added to columns
23 and 24 at final
concentration of 83 nM
6 Add library
compounds
50 nL Compounds added to columns
3–22 at final concentration of
4.2mM
7 Incubation 4 h 37C, 5% CO2
8 Media change Removed 40 mL and added
50 mL of media





1. Plated in 384-well NUNC poly-d-lysine-coated, black/clear bottom tissue
culture-treated plates.
3. The Biomek NX with 96-well head was used to remove and add media.
4. DMSO controls were used for minimum signal of homo-FRET FP.
5. Bafilomycin-treated wells were used for maximum signal of HF-FP.
6. Prestwick Chemical Library and Enzo Life Sciences natural product library
were tested. Pintool was used to transfer the compounds into the assay
plates. Final DMSO concentration was 0.1%.
8. The Biomek NX with 96-well head was used to remove and add media.
9. Plates were read from the top.
FP, fluorescence polarization; FRET, Förster resonance energy transfer.
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promoter). The transduced islets show discrete b-cell labeling
when the islets are costained for glucagon (Fig. 3D). However, a
partial colocalization was observed between PPI-mCherry and
immunostained endogenous insulin in the transduced islets
(Fig. 3E).
We have also observed that the PPI-mCherry protein is
secreted through normal insulin secretory channels and can
be directly detected by measuring mCherry fluorescence se-
creted into the media. GSIS was performed using the PPI-
mCherry INS-1 cell line and we
observed an approximate two-
fold glucose-stimulated release of
the PPI-mCherry reporter in high
glucose media compared with no
glucose media (Fig. 4A). The pa-
rental INS-1 cells have histori-
cally shown a two- to three-fold
GSIS over baseline.15 The addition
of exendin-4 (10 nM) displayed a
synergistic response with high
glucose (2.7-fold compared to low
glucose). This response was in-
hibited by the calcium channel
blocker nifedipine that is known
to inhibit insulin release.19 These
data suggest that PPI-mCherry
reporter system: (1) undergoes
GSIS and does not interfere with secretion of endogenous in-
sulin and, (2) responds normally to known insulin-modulating
compounds, such as exendin-4 and nifedipine in similar
quantitative fashion as insulin.
Labeling of primary human islets was performed with len-
tiviral transduction of the PPI-mCherry reporter system and
proof-of-principal of b-cell sorting was performed. Figure 4B
shows adequate separation for sorting in the mCherry chan-
nel. Following sorting, mCherry-positive cells were seeded
Fig. 3. PPI-mCherry reporter system. (A) Schematic diagram of PPI-mCherry reporter construct. A part of C-peptide and entire A chain of
mouse preproinsulin (PPI) II were replaced with mCherry. (B) Immunofluorescent image of transfected INS-1 cells with PPI-mCherry
reporter. (C) Colocalization of PPI-mCherry with insulin in INS-1 cells. The yellow/orange color indicated a high extent of colocalization of
PPI-mCherry (red) and insulin vesicles (green) in the INS-1 cells. In the human islets, glucagon (green) was not colocalized with the mCherry
reporter. (D) The extent of colocalization of PPI-mCherry reporter and insulin (green) was not significant (E). (nuclei = blue).
Fig. 4. Validation and utilization of the biosensor using a fluorescent PPI reporter. (A) Glucose and
exendin-4 stimulated insulin secretion. Inset shows relative fluorescent intensity of secreted
mCherry-insulin. (B) Flow cytometry histogram for primary human b-cell sorting. LG, low glucose
(5.6 mM); HG, high glucose (25 mM); Ex, exendin-4 10 nM; NF, nifedipine 10 mM; RFU, relative
fluorescence units.
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onto 384-well plate (2,000/well) and automated microscopy
was performed to capture three-color multiplexed images for
each well; nuclei (blue—Hoechst-33342—cell permeant nucleic
acid stain), viability (green—YoYo-1 iodide, cell impermeant
nucleic acid stain), and insulin (red—PPI-mCherry). Image
analysis is subsequently performed to tabulate the number of
cells/well, live:dead score based on the percentage of YoYo-1-
positive cells, and b-cell confirmation by mCherry. Post sorted
b-cells were found to be highly viable after 3 days in culture
(>95%), and the mCherry-positive b-cells comprised over 85%.
The maximum theoretical yield for b-cells from dispersed islets
is *70%. We obtained *50% yield from a small batch of
250,000 dispersed cells yielding *140,000 b-cells.
Live cell kinetic imaging was performed using our reporter
system to visualize intracellular insulin vesicle movement,
and localization (e.g., readily releasable vs. reserve pools).
Immediately after adding high glucose (25 mM) medium with
10 nM of exendin-4, high-content time-lapse imaging was
performed. Supplementary Video S1 (Supplementary Data are
available online at www.liebertpub.com/adt) shows real-time
insulin vesicle movement in live cells during a glucose chal-
lenge. Overall, there was an outward mobilization of the re-
serve pool population toward the cell membrane that indicates
increased insulin vesicle trafficking to replenish the RRP
(Supplementary Fig. S1).
Assay Development to Identity Modulators
of Insulin Granule Packaging
Parental INS-1 and the transfected INS-1 with PPI-mCherry
were carried in parallel in all initial studies. The total fluo-
rescent intensity in the red (675/50 nm) of parental INS-1 was
similar to background wells with media alone. Bafilomycin is
a vacuolar-type H+ ATPase (V-ATPase) inhibitor that prevents
insulin granule formation by inhibiting maturation of vacu-
oles.20 To validate bafilomycin as a positive control for the
HF-FP assay, optimization of bafilomycin concentration and
incubation time were performed. The performance of FP assay
was evaluated using Z0-factor and was calculated using the
equation, where s is standard deviation of positive control
(maximum signal control; bafilomycin-treated) or negative
Fig. 5. Correlation between HF-FP signal and high-content endpoints and a Min–Max assay validation. (A) INS-1 PPI-mCherry vehicle control
cells showing a granular insulin expression pattern. (B) 100 nM bafilomycin-treated cells showing a smooth expression pattern. (C) Partial
least squares (PLSs) analysis revealed a strong anticorrelation between HF-FP signal and mCherry granularity. (D) Min–Max assay
validation in 192 wells from three 96-well plates showing incubation with positive control (100 nM bafilomycin) and negative control (DMSO
vehicle). The dotted lines indicate the range of m– 3s of positive and negative controls. The data are mean – SE of four replicates.
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control (minimum signal control; DMSO alone) and m is the
mean of the positive control or negative control:
Z0 - factor = 1 - [3rmax + 3rmin]=[lmax - lmin]:
Four-hour incubation with 100 nM bafilomycin resulted in
maximum change in FP relative to negative control, providing
the maximum assay window and the Z0-factor was greater
than 0.5.
To aid in the interpretation of the FP phenomenon, PLS
regression analysis was performed following high-content
imaging. Cells were treated with 0.1–200 nM of bafilomycin
and FP was measured using the PHERAstar plate reader. The
plate was immediately fixed and stained with Hoechst-33342
and was imaged using a BD Pathway 855 BioImager. Figure
5A shows the negative control condition exhibiting a nor-
mal granular mCherry expression pattern. Figure 5B shows
100 nM bafilomycin-treated cells with a smooth mCherry
expression pattern. PLSs regression analysis was performed at
each bafilomycin concentration with high-content features as
factors (X’s), and were regressed against the FP value as the
response variable (Y) to discover the high-content features
most highly correlated with the FP signal. PLS analysis dem-
onstrated high anticorrelation with the quantified granularity
indicating that the HF-FP assay was primarily measuring the
granularity of the PPI-mCherry signal (Fig. 5C). The calculated
EC50 values of bafilomycin for FP and granularity were nearly
identical at 23.3 and 24.0 nM, respectively.
To assess the day-to-day variability, a Min–Max experiment
using 100 nM bafilomycin was performed on three different
days (Fig. 5D). The coefficient of variation (CV) was 0.75% and
0.64% for Min control and Max control,
respectively, and the 3-day variability
was less than 5%. The calculated Z0-
factor for each plate from three different
days were 0.60 (plate 1, green), 0.57
(plate 2, black), and 0.68 (plate 3, red),
respectively, indicating the suitability of
the assay for HTS.
To examine the performance of the
HF-FP assay in 384-well format, 20,000,
40,000, 60,000, and 80,000 cells/well
seeding densities were assessed with 4 h
incubation of 83nM bafilomycin and
80,000 cells/well seeding density pro-
vided the maximum assay window in
384-well format. There were no signif-
icant differences in parallel and per-
pendicular intensities, and FP between
96- and 384-well plate formats. A Z0-factor over 0.5 was
calculated for 384-well format when 80,000 cells/well seeding
density and 83nM bafilomycin were used (data not shown).
Pilot Screening in 384-Well Plate Format
We performed pilot screening using Prestwick and Enzo
384-well format for concentration range finding and to de-
termine the confirmation rate. Plate-based normalization
was performed using the mean polarization values of nega-
tive and positive controls, yielding percent inhibition from 0
to 100. The normalized FP is plotted for each compound in
Figure 6A after omitting, for clarity, two hits that show
202.8% inhibition and -639.2% inhibition. Compounds were
identified as hits if the mP values were above or below the
95% CL (approximately m – 3s). The averaged Z0-factor from
this 1,782 compound pilot screen was 0.52, with a hit rate of
1.4%. Twenty-six compounds were active. Antimycin A1
was selected from both FDA-approved and natural product
libraries.
A histogram and box plot with a normal statistical distri-
bution of compound activities are shown in Figure 6B and C.
Eleven compounds out of the 26 selected compounds were
screened in triplicate for dose–response determination and 4
were confirmed in this assay, yielding a confirmation rate of
36.4%. Antimycin A1, oligomycin A, and rotenone signifi-
cantly decreased FP (Fig. 7A–C) and Chicago Sky Blue 6B
significantly increased FP in a dose-dependent manner.
However, Chicago Sky Blue 6B was considered a false positive
due to fluorescence in the same spectral region as mCherry
and it was not possible to separate its contribution to the
overall FP signal. Figure 7D shows that antimycin A1
Fig. 6. FP data from pilot screen. (A) Scatterplot for 1,782 test compounds (green circle),
negative control (DMSO; red triangle), and positive control (Bafilomycin; blue triangle). The
arrows indicate antimycin A1 that were selected from both Prestwick and Enzo chemical
libraries. (B) Histogram indicating normal statistical distribution of compounds (mean – SD;
367.9 – 7.3). (C) Box plot showing distribution statistics and outlier compounds.
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significantly increased granularity of PPI-mCherry signal in a
dose-responsive manner, indicating that decrease in FP cor-
relates with increase in insulin granularity, as shown in the
PLS regression analysis.
DISCUSSION
Currently, there is a significant unmet medical need in the
management of T2Ds. With only 36% of diabetes patients
achieving their HbA1c goal of £7%, there is a dramatic need
for new therapeutic approaches for the management of T2Ds.9
One aspect of insulin production by the b-cell that has been
elusive to drug discovery efforts is modulation of insulin
granule packaging and trafficking. In this study, we present a
high-throughput technique to assess insulin granule dynam-
ics in cell lines that can be used to characterize pharma-
cological effects on granule formation and release. This
technology provides a unique tool to assess an aspect of b-cell
biology that has been inaccessible to HTS and can potentially
lead to the discovery of small molecules that enhance insulin
processing and delivery by the b-cell. This phenotypic drug
discovery approach can also lead to the identification of novel
molecular targets and new therapeutic strategies for the
treatment of diabetes.
Utility and Benefits of PPI-mCherry Reporter System
In this study we present a genetically encoded mCherry-
insulin reporter system that can be used in several ways,
including live cell imaging of insulin and its dynamics, simple
GSIS measurements, viable b-cell sorting, and live cell
tracking of insulin granule dynamics with FP through homo-
FRET interactions. This reporter system is generally respon-
sive to known insulin modulating compounds and can be used
as a surrogate signal in lieu of costly insulin immunolabeling
approaches.
The current standard for detecting insulin secretion in GSIS
is using insulin-ELISA. ELISA assays require expensive
Fig. 7. Dose–response confirmation of active compounds that significantly decreased FP. (A) Oligomycin A, EC50 = 0.114 mM. (B) Antimycin
A1, EC50 = 0.089 mM. (C) Rotenone, EC50 = 0.37 mM. (D) Antimycin A1 increased granularity in a dose-dependent manner. Dotted lines depict
the range of m – 3s. Each value represents the mean – SD of three replicates.
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reagents, including monoclonal antibodies and time-consum-
ing assay optimization. Our reporter system allows the mea-
surement of endpoint insulin secretion in a simpler way, by
direct quantitation of media containing insulin-mCherry fusion
protein using a fluorescence detector. Cell culture supernatant
can simply be deposited onto a membrane and directly imaged
using a TRITC filter set or in the 780 nm channel on an IR-based
flat-bed scanner. While this technique is simple, it requires
larger volumes of cell culture supernatant (*800mL, and is
most suitable to larger formats (e.g., six-well dishes of cells).
Assay Development to Identify Regulators of Insulin
Granule Packaging Using Homo-FRET
Through Polarization
In an effort to develop a high-throughput assay to monitor
insulin production, we initially attempted to use a mouse in-
sulin promoter-driven PPI-mCherry construct with the hopes
of detecting increases in insulin by monitoring mCherry
fluorescence, but driven by a bona fide insulin promoter.
Unfortunately, we did not observe significant differences in
mCherry signal under glucose stimulation and chose instead
to refocus the assay on insulin maturation, packaging, and
distribution in the cell using high-content imaging. We also
hypothesized that measuring FP of mCherry in live cells could
yield information about insulin packaging. Indeed, a sub-
stantial difference in the FP signal was observed, but in the
opposite direction, as predicted just considering the change in
the tumbling rate of mCherry. Initial assumptions were that
bafilomycin would cause a decrease in mCherry FP signal due
to the increased tumbling rate of mCherry when not packaged
into a granule. The observed effect was a large increase in the
FP signal upon bafilomycin treatment, indicating an alter-
native mechanism. When insulin granules are tightly pack-
aged in untreated control cells, the mCherry intermolecular
distance decreases and homo-FRET increases. In this config-
uration, the excited state can hop from molecule to molecule,
thereby randomizing the initial polarization information,
which results in an apparent decrease of mCherry polariza-
tion. When PPI-mCherry-transfected cells receive bafilomy-
cin, the insulin granule packaging and maturation process is
inhibited and PPI-mCherry insulin fusion proteins are present
mostly as monomers. Then, polarization of mCherry increases
due to an inhibition of homo-FRET, caused by increased in-
termolecular distance of mCherry. Fluorescent images con-
firm that the PPI-mCherry-transfected cells were responsive to
bafilomycin by demonstrating a diffuse pattern of mCherry,
compared to untreated cells, which showed an intense punc-
tate pattern of mCherry. Using bafilomycin as a positive
control, we optimized the HF-FP assay to indicate the degree
of insulin granule formation as measured by changes in FP of
mCherry for both 96- and 384-well formats. We also suc-
cessfully performed pilot screening in 384-well format.
Three compounds, antimycin A1, oligomycin A, and
rotenone were discovered in the pilot screen and exhibited a
dose-responsive decrease in FP. These compounds are mito-
chondrial toxins that inhibit the electron transport chain of
oxidative phosphorylation at different stages.21 Antimycin A1
inhibits electron transfer in complex-III by inhibiting the
oxidation of ubiquinol by Cyt bc1. Rotenone, an inhibitor of
NADH dehydrogenase, and oligomycin A, an inhibitor of ATP
synthase, inhibit the electron transfer in complex-I and V,
respectively. In pancreatic b-cells, mitochondrial oxidative
phosphorylation accounts for approximately 98% of ATP
production.22 Glucose is metabolized through mitochondrial
oxidative phosphorylation and produces ATP. Numerous
studies have demonstrated that antimycin A1, oligomycin A,
and rotenone inhibit GSIS by interrupting mitochondrial
oxidative phosphorylation.21,23,24 The decreased ATP/ADP
ratio by these mitochondrial toxins inhibits closure of ATP-
sensitive K+ channels, suppressing calcium influx and insulin
secretion. In this assay, the shift in equilibrium to more tightly
packaged mature insulin granules due to suppressed insu-
lin secretion enhances homo-FRET and decreases FP. This
phenomenon is verified by our result that insulin secretion
inhibitors, antimycin A1, oligomycin A, and rotenone signif-
icantly decrease mCherry polarization. Additionally, in high-
content imaging, an increase of antimycin A1 concentration
significantly increased granularity in a dose-dependent man-
ner indicating more tightly packaged mature insulin granules
due to suppressed insulin secretion.
In conclusion, this insulin reporter system and HTS platform
delivers a viable approach for phenotypic drug discovery for the
identification of compounds that alter insulin granule packaging
and insulin release and provides useful tools for live-cell imaging
of insulin dynamics in b-cells. Additionally, we established a
novel cell-based FP biosensor using a fluorescent PPI reporter to
identify compounds that modulate insulin granule packaging.
Several compounds were identified in this study that supported
our assay mechanism, demonstrating that this assay tool is ca-
pable of a large-scale library screening. To expand on this study,
the HF-FP approach needs to be evaluated for other fluorescent
proteins and biological systems. This technology can provide a
valuable new modality for HTS to assess protein–protein inter-
actions and dynamics in live-cell systems.
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BSA ¼ bovine serum albumin
CMV ¼ cytomegalovirus
DMEM ¼ Dulbecco’s modified Eagle’s medium
DMSO ¼ dimethyl sulfoxide
FBS ¼ fetal bovine serum
FP ¼ fluorescence polarization
FRET ¼ Förster resonance energy transfer
GFP ¼ green fluorescent protein
GLP-1 ¼ glucagon-like peptide-1
GLP-1R ¼ glucagon-like peptide-1 receptor
GSIS ¼ glucose-stimulated insulin secretion
HTS ¼ high-throughput screening
INS-1 ¼ rat insulinoma cells
PBS ¼ phosphate-buffered saline
PLS ¼ partial least squares
PPI ¼ preproinsulin
RRP ¼ readily releasable pool
T2D ¼ type 2 diabetes
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